secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001558370-23-005150
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech reports record FY2022 revenue $75.7M, net loss $(86.6)M; BLA accepted for cosibelimab
--------------------------------------------------------------------------------

- Record consolidated net revenue of $75.7M for FY2022, up from $68.8M in FY2021; $71.0M from dermatology products.
- GAAP net loss attributable to common stockholders of $(86.6)M ($(0.97)/share) vs $(64.7)M ($(0.79)/share) in FY2021.
- Cash, equivalents and restricted cash $181.0M at Dec 31, 2022, down from $308.0M at Dec 31, 2021.
- FDA accepted BLA for cosibelimab (anti-PD-L1) for cSCC; PDUFA goal date Jan 3, 2024; no advisory committee planned.
- Expects to complete rolling NDA for CUTX-101 (Menkes disease) and submit NDA for DFD-29 (rosacea) in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837023005150/0001558370-23-005150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837023005150/fbio-20230330x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-005150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer